Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Botox for prevention of radioiodine-induced sialadenitis
IRCT20230627058597N1Phase 2Completed
- Sponsor
- Tehran University of Medical Sciences
- Start
- Aug 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of botulinum toxin type A in sialadenitis (2 arms), sponsored by Tehran University of Medical Sciences. Primary endpoints: Clinical salivary gland inflammation signs, Pain or burning during eating and 2 more. Started Aug 2023; status: completed.
02
Drugs
botulinum toxin type A
03
Conditions
sialadenitis
Beyond the preview
Go deeper on IRCT20230627058597N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20230627058597N1.